During preservation, donated liquid red blood cells (RBCs) experience multiple functional and structural changes known as the storage lesion. Increased RBC age is associated with increased infection rates, organ failure, and mortality.
A nemia in trauma patients is secondary to traumatic hemorrhage and the resulting coagulopathy. Subsequent resuscitation, surgical interventions, and serial blood draws result in further anemia. Red blood cell (RBC) production in these patients is often abnormal, and they are not able to recover from losses. As a consequence of anemia, many critically ill patients receive packed RBC (PRBC) transfusions. The average intensive care unit patient receives 5 units of PRBCs. 1 There are several well-accepted reasons to administer a PRBC transfusion including restoration and maintenance of intravascular volume, activation of platelet-driven hemostasis, restoration of tissue perfusion, and prevention of the development of organ failure and death.
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Blood transfusion is a critical therapeutic option. 5 Unfortunately, there are seasonal or cyclical blood shortages that affect patient management. According to America's Blood Centers STOPLIGHT, blood availability monitoring program, on average, approximately 30% of national reporting sites had an available blood supply of only 2 days or less. 6 Blood collected after national disasters usually takes 2 days to reach blood banks representing too long of a delay to be of immediate use to victims. Banked donor blood is a mixture of cells with different ages and definite life spans. Standard preservation for banked blood is at a refrigerated temperature of 2-C to 8-C. These conditions decrease erythrocyte metabolism, yet donor RBCs still experience a series of functional and structural changes, which are collectively referred to as a storage lesion. 7 Multiple elements contributing to the storage lesion have been described, including changes in nitric oxide (NO) metabolism, free hemoglobin, depletion of 2,3-Diphosphyglycerate (2,3-DPG), altered morphology, hemolysis, and residual leukocytes and platelets. The storage lesion manifests with various speeds as the age of the donor RBCs differ.
In 1950, Smith 8 showed that a small amount of blood, mixed with glycerol, could be cooled to j70-C. A short time later, this technique was used to freeze, thaw, and deglycerolize human RBCs while retaining normal viability. 9 A number of cell-specific cryopreservation protocols have been developed. The methods differ with regard to cell concentrations, protective solutions used, freezing and thawing rates required, storage temperature, and postthaw processing. A high glycerol/ slow cooling process is the preferred method in the United States. 10 Controlled addition and removal of glycerol is required to prevent osmotic lysis of the RBCs. Standards set by the American Association of Blood Banks require RBCs to be frozen within 6 days of collection. 11 In September 1987, the Food and Drug Administration (FDA) approved a 10-year storage period for glycerol-frozen RBCs maintained at j80-C. 12 Previously, the glycerolization and deglycerolization processes were performed in a functionally open system. It was a labor intensive, technically demanding process with a postwash RBC storage period of only 24 hours. 13 The Haemonetics Corporation (Braintree, MA) developed and introduced the Automated Cell Processor (ACP) 215 for the thawing and deglycerolization of RBC units. This functionally closed and easy to operate system allows sequential processing of 2 RBC units. When the ACP 215 is used for processing, the FDA has approved extended postthaw storage of frozen RBCs for up to 14 days at 4-C in standard storage solutions. 14 There is a growing body of evidence indicating that the duration of storage may affect the efficacy and safety of blood products. Ideally, a fresh product could be supplied to all recipients. However, in the absence of convincing data to support shortening, the duration of refrigerated blood storage and the subsequent negative impact on blood bank inventory cannot be justified. During periods of high demand and low donation, typically during summer months, much of the national banked blood inventory is within days of expiring. Thus, reducing the storage period by as little as 1 week could significantly reduce the amount of available blood. Cryopreserved blood represents a possible method of solving this problem by avoiding the storage lesion without reducing the available blood supply. While there has been use of frozen RBCs in civilian and military practice, widespread application in the civilian setting has not yet occurred.
15Y17 Based on the theoretical advantages of cryopreserved blood, we performed a pilot study to compare tissue oxygenation in patients receiving cryopreserved blood versus standard refrigerated blood. Clinical outcomes were assessed, looking for evidence of gross safety issues with cryopreserved blood, recognizing that the study was not adequately powered to make strong conclusions.
HYPOTHESIS
We hypothesized that transfusion of cryopreserved blood would be superior to transfusion of standard liquid PRBCs with respect to tissue oxygenation.
RESEARCH DESIGN AND METHODS
This was a prospective, randomized, double-blinded pilot study. Patients were considered candidates if admitted to the Oregon Health and Science University trauma service with an Injury Severity Score (ISS) of greater than 4 and expected to require PRBC transfusion. Consent from the patient or a legal representative before the transfusion of the first unit was required for admission into the study. This excluded patients who required emergent interventions or for whom consent was unobtainable. Other exclusion criteria included the need for massive transfusion any time within the previous 3 months, any RBC transfusion in the preceding 24 hours, age less than 15 years, or pregnancy. The thawing and deglycerolization process takes approximately 2 hours. For this reason, hemodynamically unstable patients and patients whose physicians believed that waiting 3 hours to receive the transfusion could be potentially harmful, were excluded. In addition, patients were excluded for bilateral upper extremity injuries preventing placement of a tissue oxygenation (StO 2 ) monitor on the thenar eminence. Anemic patients fitting the inclusion criteria or their respective legal representatives were approached for consent. Demographic data were collected on enrolled patients receiving PRBC transfusion including sex, age, and ISS. Clinical outcomes such as length of stay, organ failure, transfusion reactions, deep venous thrombosis, and mortality were also documented. Once enrolled, the blood bank was notified to randomize the patient in preparation for any subsequent PRBC transfusion. Randomization was determined by a random numbers generating program and patient allocation was determined by filling the next line on a list of group assignments. Patients were randomized to three groups: younger refrigerated blood less than 15 days, older refrigerated blood 15 days to 42 days, and cryopreserved cells. In this pilot study, there were no substantial differences between the refrigerated blood groups so they were combined to increase the power of the analysis. All decisions to administer PRBCs were at the discretion of the primary treatment team. The general threshold for transfusion in our facility is hemoglobin less than 7 g/dL except for patients with severe head injury in whom the threshold is hemoglobin less than 8 g/dL. Thawing and deglycerolization was performed at the time of randomization, and units were transfused within 3 days of thawing. After thaw, cells were preserved in AS-3 solution at 4-C. While FDA guidelines allow use of cryopreserved RBCs up to 14 days after thawing, all units were transfused within 72 hours to minimize confounding comparisons.
The method of cross-matching varied, depending on the patient's antibody screen results. Antiglobulin, a serologic test, was performed by the Gel microtube methods when the patient's serum was found to be without antibodies. When no antibodies were present and there were no discrepancies in the ABO, RH type, an electronic cross-match was performed. When no antibodies were present, and the patient was otherwise ineligible for computer cross-match, an immediate spin serologic test was performed.
Once a transfusion order was placed for an enrolled patient, a near-infrared spectroscopy device (Hutchinson Technology, Hutchinson, MN) was placed before RBC administration, and tissue oxygenation (StO 2 ) was measured continuously for at least 12 hours after completion of the transfusion. This device uses a thenar eminence sensor pad to assess tissue oxygenation (StO 2 ). In patients with radial arterial lines or those with upper extremity injuries, the sensor was placed on the other hand. Near-infrared spectroscopy is a previously validated monitoring system that measures tissue perfusion noninvasively using near-infrared light to assess the ratio of oxygenated hemoglobin to total hemoglobin in the underlying tissue. 18 A baseline blood sample was collected before RBC transfusion and a subsequent sample was collected at completion of the first RBC unit. In the event that a second unit was administered, an additional sample was taken upon its completion. An interval blood sample was then obtained 12 hours after completion of transfusion. Based on data showing the association between blood cell transfusion and venous thromboembolism, thrombelastography (TEG) was performed on all samples to evaluate coagulation status. 19 A complete blood count was also performed.
Organ failure data were collected to assess for gross safety issues. Adult respiratory distress syndrome was defined as outlined by the American-European consensus conference. 20 Multiorgan failure was graded using the Denver Multiorgan Failure score. 21 Acute renal failure was assessed using the RIFLE classification as outlined by the Acute Dialysis Qualitative Initiative Workgroup. 22 Changes in StO 2 were defined as median differences in maximum or minimum StO 2 during the transfusion and posttransfusion periods compared with baseline values. To avoid minute-to-minute variations, which are characteristic of StO 2 measurements and to better characterize trends, an area under the curve (AUC) analysis was performed. The AUC during the baseline, transfusion, and posttransfusion periods was measured and compared within and between groups. StO 2 data were found to be normally distributed and therefore were evaluated using a Student's t tests.
To determine the effects of blood age and preservation technique on clinical outcomes, continuous variables were analyzed by Student's t tests. Nonparametric results were analyzed using a Mann-Whitney U-test. A multivariate analysis was performed to control for important clinical variables to include injury severity, mechanism of injury, and sex.
RESULTS
Fifty-seven trauma patients were enrolled and received PRBC transfusion. Thirty-five patients received standard RBCs. Nineteen of the patients received blood stored for less than 15 days, and 16 patients received blood stored for 15 days to 42 days. Twenty-two patients were administered with cryopreserved RBCs. Of the patients who received standard RBCs, 11 (31%) received two consecutive units, compared with 9 patients (41%) who received cryopreserved RBCs (p = 0.57). The median duration of transfusion was 135 minutes (75Y 209 minutes). The median preadministration storage age of the standard units was 14 days (10Y27 days) compared with 21 months (14Y27 months) for the cryopreserved units. After thaw, all deglycerolized blood was administered within 3 days. The two groups were well matched for age, sex, trauma mechanism (blunt vs. penetrating), ISS, and Acute Physiology and Chronic Health Evaluation II scores (Table 1) .
While this pilot study was not powered to demonstrate statistically significant differences in clinical outcomes, additional data were also assessed to screen for any major safety differences. No gross differences were noted between the two groups when comparing rates of organ failure, transfusion reactions, deep venous thrombosis, or median hospital length of stay (Table 2 ). There were no differences observed in TEG parameters (Table 3) , with the exception of a slightly greater > angle in the cryopreserved group following transfusion of the second RBC unit. Hematocrit (HCT) was evaluated before transfusion, immediately after transfusion, 12 hours after transfusion, and just before discharge. No differences were noted in HCT change following transfusion between the groups (Fig. 1) .
Mean values for StO 2 tracings were compared in patients receiving cryopreserved blood and standard RBCs (Fig. 2) . Tracings were excluded if recorded data were not continuous for the duration of transfusion through the 12-hour postadministration period. This resulted in 20 evaluable patients in the cryopreserved group and 30 in the standard group. A statistically significant difference was noted when comparing the AUC of mean StO 2 data for the two groups (p = 0.03). This difference was observed from initiation of transfusion until the 180-minute time point. After that time, the differences were no longer statistically significant. Data were collected up to 12 hours after the completion of transfusion. After180 minutes, a trend of superiority continued but slowly returned to baseline (Table 4) .
Median values of standard coagulation parameters of prothrombin time, activate partial thromboplastin time, fibrinogen, and platelets are represented in (Table 5) . No differences were denoted within the groups at any time point comparison. Platelet function was significantly higher (p = 0.01) in the cryopreserved group only after the transfusion of a second unit of RBCs.
DISCUSSION
In this pilot study, we did not observe any obvious differences in clinical outcomes when cryopreserved RBCs were compared with standard RBCs. The primary difference detected Near-infrared spectroscopy has been used in a broad spectrum of clinical scenarios to assess tissue perfusion. These include cerebral monitoring during cardiovascular procedures, management of stroke and subarachnoid hemorrhage, and detection of compartment syndrome. 23Y25 Changes in StO 2 have been previously shown to be predictive of mortality in trauma patients. 18 Thus, while this study was not powered to demonstrate differences in organ failure and death, our findings correlate with factors known to impact clinical outcomes.
Kiraly et al. 26 compared StO 2 during transfusion with older RBCs, younger RBCs, and controls not receiving blood, using a cutoff of 21 days for the age of older RBCs. This study revealed that patients transfused with older blood experienced a decrease in StO 2 , while those transfused with younger blood and controls experienced no change. The mean age of the standard RBCs transfused in the current study was 14 days, and similar to the study by Kiraly et al, there was no change in StO 2 . Previous observations of the biochemical changes during hypothermic storage help to explain the differences seen in the current study and previous studies. RBCs participate in adaptive responses to oxygen concentration by regulating peripheral vasoconstriction. 27 These cells react to local changes in tissue oxygenation and adjust NO bioavailability to reflect metabolic demand. Standard refrigerated blood storage experiences a rapid loss in NO bioactivity, thus theorized to have an influence on hypoxic vasodilatation. 28 In vivo RBCs are rich in 2,3-DPG, a critical facilitator of oxygen delivery. 29 31 showed that after thawing cryopreserved cells, 2,3-DPG levels are comparable with prefreezing levels and affected only by the prestorage interval before freezing. During refrigerated storage, RBCs devolve from deformable biconcave disks to irreversibly deformed spheroechinocytes. 7 The altered morphology promotes adherence to vascular endothelium and decreases erythrocyte deformability. 32 Capillaries can be narrower than the RBCs, so as deformability is altered, the passage of RBCs is impaired. This phenomenon may contribute to decreased peripheral oxygen delivery. Changes in morphology are also associated with increased splenic sequestration of RBCs. 33 Cryopreservation halts RBC metabolism and may maintain cell morphology.
At the end of the 42-day refrigerated storage period, up to 30% of transfused RBCs are nonviable and are removed from the circulation within a few hours of administration. As blood ages, progressive hemolysis is observed. The result is increased free hemoglobin in refrigerated RBCs, which scavenges endothelialderived NO. 34 Substantial decreases in hemolysis have been described in postthaw frozen RBCs. 35 Refrigerated preservation of RBCs delays these described biochemical processes but fails to completely arrest them. Optimal RBC viability is preserved under standard refrigerated conditions for 2 weeks. However, shortening the storage period to this short of a duration for refrigerated RBCs would significantly impair donor blood supply. 37 Most importantly, transfusion of cryopreserved RBCs resulted in superior tissue oxygenation during administration compared with standard RBCs. A multicenter study of the same design is currently underway. This investigation will include biochemical data and evaluation of RBC deformability to directly assess components of the storage lesion.
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DISCUSSION
Dr. Frederick Moore (Gainesville, Florida): Dr. Fabricant has nicely presented the results of a prospective randomized trial comparing standard refrigerated stored blood to cryopreserved blood. Cryopreservation has been used in blood banking for over 50 years. The red blood cells are frozen in glycerol. This protects against ice crystal formation during freezing. The frozen blood can be stored for many years. The recommended length is ten years. In current blood banking cryopreservation has three niches. First is prolonged, autogenous blood storage. The second is preserving rare phenotypes of blood for those patients who develop antibodies to the antigens on the red blood cells. Third, a cryopreserved blood bank can serve as a bridge in the case of a disaster which disrupts the normal blood collection, processing and distribution pipelines.
I would like to emphasize three downsides to cryopreservation that limits its broader use. The first is cost. One unit of cryopreserved blood costs three or four times that of a standard unit of blood. The second is time. It takes at bare minimum 40 minutes to thaw and deglycerate a unit of frozen blood. Third is equipment and technical support. It takes a special device to thaw and deglycerate frozen blood and in setting a massive transfusion you would require multiple machines and multiple technicians. Given these limitations cryopreserved blood is not used for emergency transfusions. With that as a background, let's discuss the current study. It showed no significant differences in lab parameters and clinical outcomes between the transfused groups. That is not surprising given the sample size. Of note, however, StO 2 (which is an index of tissue perfusion) was found to be higher in the cryopreserved group from the initiation of transfusion through 180 minutes. This leads me to three questions.
First, if you look at Figure 2 in the manuscript, it looks like the differences in StO 2 are due to both a decrease in StO 2 with standard blood and an increase in StO 2 with the cryopreserved blood. In your prior work you showed that with standard blood, that patients who received old blood (greater than 21 days old) had substantial decreases in StO 2 and you have nicely described potential mechanisms. But can you explain to me how cryopreserved blood increases StO 2 ? These are stable patients who start off with a baseline StO 2 of roughly 83 %. I would not expect StO 2 to go up. And, secondly, you mentioned in the abstract the TEG parameters were similar in both groups. Could you tell me if the TEG parameters or fibrinolysis were similar in both groups? You did mention the D-dimers was elevated in standard but how did the TEG parameters look? I surmise that the increase in StO 2 is due to increased oxygen delivery. But why would it go away after 180 minutes?
Second, in your abstract you conclude, ''this finding has the potential to drive a paradigm shift.'' Would you please elucidate this paradigm? Are you suggesting that we use cryopreserved blood in acutely bleeding patients who require massive transfusion? If you could increase tissue perfusion in these patients you might substantially improve outcomes. Finally, if cryopreserved blood is limited to only stable patients, (as it is now), do you believe that an increase in StO 2 for 180 minutes post-transfusion is going to improve outcome? In summary, I would like to thank Dr. Fabricant for nicely presenting a thought-provoking study. I certainly learned something preparing for the discussion.
Dr. John R. Hall (Kingsport, Tennessee): I'd like to compliment the Oregon group for a great paper. There is conflicting data on the effect of leukocytes on red cell storage lesions, and post-transfusion infections. Other than the washing of the cells, have you seen any effect of the freezing on leukocytes?
Dr. Donald H. Jenkins (Rochester, Minnesota): My understanding is that the device of this Automated Cell Processor by Haemonetics (the ACP 215) uses a solution that also revitalizes the blood in terms of adding ATP into it. Isn't that a factor that could also be at play here?
Dr. Myung Park (Rochester, Minnesota): Can you clarify if the number of units of red blood cells given in standard versus cryopreserved groups were similar? I didn't get a sense of how much volume of products in each group was received.
And, secondly, you mentioned in the abstract the TEG parameters were similar in both groups. Could you tell me if the TEG parameters or fibrinolysis were similar in both groups? You did mention the D-dimers was elevated in standard but how did the TEG parameters look? Thank you.
Dr. Corrado Mirini (Valhalla, New York): The issue concerning the old blood is the P50 and I was wondering if you measured PHI or LLP ration in any district because low sheer redistrict would be a more important in respect to the effect of the P50 and the storage lesion?
Dr. Carrie Sims (Philadelphia, Pennsylvania): You had mentioned that nitric oxide was scavenged for the decreased nitric oxide with the stored lesion. Did you measure nitric oxide levels and whether or not the improvement in oxygen delivery was really secondary to vasodilation in your cryopreserved blood? Thank you.
Dr. Loic Fabricant (Portland, Oregon): I'd like to thank Dr. Moore for his thoughtful comments and the rest of the discussants for your questions. I will try to address them all as best I can.
So, Dr. Moore, you raised several important issues. Certainly the cost question is really, really important if we are to advocate for this system to be implemented nationally or even beyond.
You do point out a very important shortcoming which is the increased costs. We do advocate that there is some potential cost savings with a cryopreserved system. The elimination of waste should provide some offset.
Additionally, the cost associated with cancellation of elective procedures is significant. But no question this may confer a substantial cost with initial implementation.
To address your comments regarding the time and technical process in thawing the blood. Certainly for an unstable patient or a patient requiring massive transfusion you would not have the option of waiting 2 hours for blood.
What we would advocate-and this partly gets to your question about what paradigm we would propose-would be a system where the stable patient who needed transfusion would have blood matched and thawed for them, if they could tolerate waiting up to two hours, and then a system where the blood bank was prepared with previously thawed blood of a universal donor type in preparation for the unstable patient or the massive transfusion.
At this point the FDA has approved the post-thaw blood for storage under refrigerated conditions up to 14 days.
To address your question regarding the changes in StO 2 seen during transfusion, I proposed this represents a decrease in the storage lesion. Previously documented components of the storage lesion are noted to decrease with cryopreservation, including morphological changes as well as a changes in 2,3-DPG.
I think it's very likely that other components of the storage lesion are also decreased during cryopreserved storage as compared to refrigerated storage.
And regarding nitric oxide, we have not looked at this data yet. Our larger study is designed to evaluate nitric oxide concentrations.
I think, also, the washing process may provide a significant benefit. There are many unviable red cells in stored blood, removing those may help with tissue perfusion.
We know also that there are cytokines and other unwanted elements within stored red blood cells that are washed and removed with the deglycerolization process.
To address the question regarding the washing solution, we have not looked at this specifically but I do not think the solution itself contributes to superior tissue oxygenation during transfusion.
As far as the observed difference for only 180 minutes, that is a very important question. One important point is that the power of this study is small. It may be that when we proceed with our broader study we are able to characterize changes for a longer duration.
As to why our findings would make a difference in a broader context, those patients in the acute setting, when often we transfuse blood, may benefit from that short period of improved tissue oxygenation.
In addition, there is some evidence that decreased tissue perfusion, from Dr. Moore and Dr. Cohen's research, is associated with organ failure.
While those were certainly much sicker patients, I think Y and who had much lower tissue oxygenation Y that correlation may provide some benefit within these patients as well.
We did not look specifically at leukocytes but I think that's a very interesting question. There is some evidence that retained leukocytes are removed with the washing process.
And we did not specifically look at pH or P50 but certainly additional biochemical studies are intended with our future studies.
Thank you very much for the opportunity to present our findings here today.
